CurrentPremera BluecrossPolicy 8.01.532

Hematopoietic cell transplantation for germ-cell tumors

Medical coverage policy for autologous and allogeneic hematopoietic cell transplantation in individuals with germ-cell tumors, describing medically necessary and investigational indications, documentation and coding expectations for providers.

Policy Summary

PayerPremera Bluecross

PolicyHematopoietic cell transplantation for germ-cell tumors

Policy CodePolicy 8.01.532

Change TypeAnnual review — no material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and verify member benefits before hematopoietic cell transplantation services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Medically necessarySingle autologous HCT

Medically necessary (testicular)Tandem/sequential HCT

InvestigationalAutologous HCT first‑line

InvestigationalAllogeneic HCT

NCT02375204Ongoing trial

04/01/26

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Indications and Limitations

Medically necessary indications

Covered when meeting the specified clinical scenarios and prognostic factor conditions:

Single autologous HCT - salvage or relapse: Single autologous HCT may be considered medically necessary as salvage therapy for germ-cell tumors in individuals with favorable prognostic factors who have failed a previous course of conventional-dose salvage chemotherapy OR in individuals with unfavorable prognostic factors as initial treatment of first relapse (i.e., without a course of conventional-dose salvage chemotherapy) and in individuals with platinum-refractory disease.

See definitions of favorable and unfavorable prognostic factors.

Tandem/sequential autologous HCT: Tandem or sequential autologous HCT may be considered medically necessary for the treatment of testicular tumors either as salvage therapy or for platinum-refractory disease.

Applies specifically to testicular tumors.

Investigational / Not covered

Not covered / investigational indications:

Autologous HCT as first-line: Autologous HCT is considered investigational as a component of first-line treatment for germ-cell tumors.

Randomized controlled trials did not demonstrate improved outcomes for autologous HCT as initial therapy.

Allogeneic HCT is considered investigational to treat germ-cell tumors, including as therapy after a prior failed autologous HCT.

Insufficient evidence from RCTs or comparative studies; only case reports exist.

Coverage under this policy may be superseded by applicable state mandates or by specific contract provisions. Examples include state requirements or plan provisions that provide coverage for autologous bone marrow transplantation when delivered as part of National Institutes of Health–approved clinical trials, voluntary plan programs that extend trial coverage, or contract/certificate terms that identify particular circumstances in which autologous bone marrow transplantation is eligible for coverage.

This medical policy does not apply to Medicare Advantage members. Providers and members should consult the member benefit booklet or contact member services to confirm coverage and any plan-specific limits or requirements for Medicare Advantage enrollees.

Guideline-aligned coverage stance

Coverage aligns with guideline-supported use of high-dose chemotherapy with stem-cell support as salvage/second-line therapy for germ-cell tumors when consistent with plan benefits and regulatory standards.

Guideline-supported indications: High-dose chemotherapy with autologous HCT is recommended by NCCN as a preferred option for recurrent malignant ovarian germ cell tumors and as a second-line option for metastatic testicular cancer; ASTCT guidance supports autologous HCT for relapsed or refractory germ cell tumors (recommendation levels cited).

Coverage is subject to plan benefit limits and required documentation; see regulatory requirements for hematopoietic stem cells.

Line of Therapy — First-line vs. Salvage and Second-line Use

First-line and salvage

First-line: Autologous HCT as a component of first-line therapy is investigational and not supported by randomized controlled trial evidence showing improved outcomes.

RCTs did not demonstrate benefit over standard-dose chemotherapy.

Salvage: Single autologous HCT is medically necessary as salvage in specified prognostic settings (see favorable and unfavorable prognostic factors); tandem/sequential autologous HCT may be considered for testicular tumors in salvage settings.

Evidence includes RCTs and case series with variable outcomes; apply prognostic factor definitions when determining eligibility.

Second-line

Second-line/salvage: High-dose chemotherapy with stem-cell support is recognized by NCCN as a second-line option for metastatic testicular cancer and as a preferred regimen for recurrent malignant ovarian germ cell tumors; consider guideline-directed prior lines of therapy and document staging/marker status (AFP, hCG, LDH) and prognostic factors.

Covered Regimens and Trials

Regimens compared	Trial identifier & status	Population / setting	Notes
TIP (paclitaxel, ifosfamide, cisplatin)	NCT02375204 — randomized phase III; ongoing (planned completion Jun 2031)	First salvage treatment in relapsed or refractory germ cell tumors	Head-to-head comparison versus TI-CE; planned enrollment 420; listed as an ongoing key trial in the policy.
TI-CE (mobilizing paclitaxel + ifosfamide followed by high-dose carboplatin and etoposide)	NCT02375204 — randomized phase III; ongoing (planned completion Jun 2031)	First salvage treatment in relapsed or refractory germ cell tumors	Evaluated as high-dose chemotherapy approach with stem-cell support compared to conventional-dose TIP; included in Table 1 of ongoing trials.

Regimen / approach	Indication / guideline context	Coverage stance
High-dose chemotherapy with autologous hematopoietic stem-cell rescue (various regimens referenced in literature, e.g., high-dose carboplatin + etoposide following mobilization)	Recommended by NCCN for recurrent malignant ovarian germ cell tumors (preferred) and listed among second-line options for metastatic testicular cancer; ASTCT guidance supports autologous HCT for relapse/refractory germ cell tumors (recommendation levels C/S)	Covered
Tandem or sequential autologous HCT (as described in literature for testicular tumors)	Considered in guideline and literature contexts for salvage or platinum-refractory testicular germ cell tumors	Covered

Provider Actions — Authorization, Documentation, and Sequencing

Prior Authorization

Transplant-related CPT/HCPCS codes — Prior authorization is required

Prior authorization is required for hematopoietic cell transplantation (HCT) and related services billed with the listed CPT and HCPCS codes. Providers must obtain authorization before scheduling HCT services.

Affected codes include CPT 38230, 38232, 38240, 38241 and HCPCS S2142, S2150.

Note

Verify member benefits and prior authorization

Providers should verify member benefit coverage and any prior authorization requirements with Premera before delivering services. Benefit limitations, plan exclusions, or medical necessity criteria in the member’s contract may affect coverage.

Check member benefit booklet or contact member services to confirm coverage and prior authorization needs.

Prior Authorization

Coding — CPT and HCPCS

CPT codes for HCT proceduresCPT

38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241	Hematopoietic progenitor cell (HPC); autologous transplantation

HCPCS codes for HCT servicesHCPCS

S2142

Cord blood derived stem cell transplantation, allogeneic

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications including phoresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition

Transplant-related CPT/HCPCS codes (removed/updated historically)mixed

No codes listed

Biomarker Requirements for Staging and Assessment

AFP, hCG, LDH — TNM/marker S‑stage (S0–S3)

MarkersAFP (alpha-fetoprotein), hCG (human beta‑chorionic gonadotropin), LDH (lactate dehydrogenase)

PurposeUsed for risk stratification and TNM/marker staging (S‑stage categories S0–S3)

S0 definitionNo marker elevations (used for stages IA–IB testicular tumors)

S1–S3S1 = at least one marker moderately elevated; S2–S3 = higher marker elevations associated with distant metastases or worse prognosis

Clinical useMarkers contribute to grouping into good, intermediate, or poor risk categories alongside site and extent of disease

Definitions and Prognostic Factors

Autologous hematopoietic cell transplantation (HCT)

Autologous HCT — definitionHematopoietic stem cells are harvested from the patient and returned to the same patient after high‑dose chemotherapy to restore marrow function

Source of stem cellsCells may be harvested from peripheral blood, bone marrow, or umbilical cord blood (when applicable)

Immunologic compatibilityAutologous transplants do not require donor–recipient HLA matching because cells are the patient’s own

Allogeneic hematopoietic cell transplantation (HCT)

Allogeneic HCT — definitionHematopoietic stem cells are obtained from a donor and infused into the recipient to restore marrow function

HLA compatibilitySuccessful allogeneic HCT requires assessment of immunologic compatibility by HLA typing (A, B, DR loci) to identify an acceptable donor

Background — Disease and Regulatory Context

Germ-cell tumors originate from germ cells and most commonly arise in the ovaries or testicles, though they may also occur at extragonadal sites. Treatment selection is guided by primary site, histology, stage, and response to chemotherapy; standard options include surgery, radiation, and conventional-dose chemotherapy. In relapsed or refractory cases, high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) is an option considered in salvage settings, whereas allogeneic HCT remains investigational for germ-cell tumors and is not routinely recommended.

Hematopoietic stem cells and related human cells and tissues intended for implantation, transplantation, or infusion are regulated by the U.S. Food and Drug Administration under 21 CFR parts 1270 and 1271. Documentation and handling of hematopoietic stem cells used in transplantation should comply with these federal regulations.

Revision History and Review Cycle

2026-04-01annual_reviewLatest

Annual review completed; literature updated through December 9, 2025; policy statements unchanged.

2020-05-01annual_review

Annual review approved April 23, 2020 with literature review through November 2019; policy updated.

2014-06-09policy_creation

Policy Summary

PayerPremera Bluecross

PolicyHematopoietic cell transplantation for germ-cell tumors

Policy CodePolicy 8.01.532

Change TypeAnnual review — no material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and verify member benefits before hematopoietic cell transplantation services.

SourceLink

On This Page

Exact sequencing and prior-line requirements are specified in guideline documents and other sections of this policy.

Single autologous HCT may be considered medically necessary as salvage therapy for germ-cell tumors in specified clinical scenarios (see Policy Coverage Criteria). Use single autologous HCT as salvage after failure of conventional-dose salvage chemotherapy per criteria.

Single autologous HCT: medically necessary as salvage after failed conventional‑dose salvage chemotherapy or in initial treatment of first relapse with unfavorable prognostic factors, and for platinum‑refractory disease.

Note

Guideline-informed sequencing

Use guideline-supported sequencing when selecting second-line therapy. NCCN and ASTCT recommendations recognizing high‑dose chemotherapy with stem cell support as preferred or recommended second‑line therapy for recurrent or metastatic germ cell tumors should inform care decisions and authorization requests.

Document why guideline‑recommended sequencing (e.g., high‑dose chemotherapy with stem cell support) applies to the member’s clinical scenario.
When applicable, indicate prior lines of therapy and rationale for proceeding to HCT as second‑line treatment.

Documentation Required

Required documentation

The individual’s medical records submitted for review must document that medical necessity criteria are met. Include clinical documentation of diagnosis, history and physical exam, prior treatments, and prognostic factors.

Record must include: diagnosis/condition; history & physical documenting severity; prior treatments received; documentation of favorable vs unfavorable prognostic factors.

Documentation Required

Regulatory and benefits documentation

Documentation supporting the authorization should reflect compliance with federal regulations when applicable and the member’s benefit requirements. Hematopoietic stem cells are regulated under 21 CFR parts 1270 and 1271; indicate adherence where relevant.

Include records showing compliance with FDA regulations for human cells and tissues (21 CFR parts 1270 & 1271) when applicable.
Ensure documentation addresses any specific benefit plan limitations or exclusions.

Denial Risk

Investigational indications may be denied

Requests for autologous HCT as a component of first‑line treatment for germ‑cell tumors or for allogeneic HCT to treat germ‑cell tumors may be denied as investigational. If pursuing these options, provide strong supporting evidence and clinical rationale.

Autologous HCT as component of first‑line treatment: considered investigational and may be denied.
Allogeneic HCT for germ‑cell tumors: considered investigational and may be denied.

Note

No Medicare NCD

The absence of a Medicare national coverage determination (NCD) does not by itself require coverage. Coverage decisions should follow policy criteria, clinical evidence, and benefit terms.

There is no Medicare NCD for HCT in this indication; authorize based on policy medical necessity criteria and member benefits.

Immunosuppression requirementAllogeneic transplantation typically requires immunosuppression to manage graft‑versus‑host disease and other immune complications

Favorable prognostic factors

Primary siteTestis or retroperitoneal primary site

Response to initial therapyComplete response to initial chemotherapy

Serum markersLow levels of serum markers (AFP, hCG, LDH)

Disease burdenLow‑volume disease

Most actionableIndividuals with these favorable factors may be considered for single autologous HCT as salvage after failure of conventional‑dose salvage chemotherapy

Unfavorable prognostic factors

Primary siteExtratesticular (extra‑testicular) primary site

Response to initial therapyIncomplete response to initial therapy

Serum markersHigh serum marker levels (AFP, hCG, LDH)

Disease burdenHigh‑volume disease or relapsing mediastinal nonseminomatous germ cell tumors

Most actionablePresence of these unfavorable factors may indicate need for more aggressive salvage approaches; single autologous HCT can be used as initial treatment of first relapse

Hematopoietic cell transplantation (HCT) - definition

HCT — definitionHigh‑dose chemotherapy followed by infusion of autologous or allogeneic hematopoietic cells to restore bone marrow function

Cell sourcesHematopoietic stem cells may be obtained from bone marrow, peripheral blood, or umbilical cord blood

RegulationHematopoietic stem cells are regulated by the FDA under 21 CFR parts 1270 and 1271

Indications contextHigh‑dose chemotherapy with stem‑cell support is recommended by guidelines (NCCN) as a preferred second‑line/salvage option for recurrent germ‑cell tumors when consistent with plan benefits

New policy established replacing prior policy 8.01.35 after literature review through March 5, 2014.